188 related articles for article (PubMed ID: 32998229)
1. Investigation of a Pharmacological Approach for Reduction of Renal Uptake of Radiolabeled ADAPT Scaffold Protein.
Vorobyeva A; Oroujeni M; Lindbo S; Hober S; Xu T; Liu Y; Rinne SS; Garousi J
Molecules; 2020 Sep; 25(19):. PubMed ID: 32998229
[TBL] [Abstract][Full Text] [Related]
2. On the prevention of kidney uptake of radiolabeled DARPins.
Altai M; Garousi J; Rinne SS; Schulga A; Deyev S; Vorobyeva A
EJNMMI Res; 2020 Feb; 10(1):7. PubMed ID: 32020413
[TBL] [Abstract][Full Text] [Related]
3. Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules.
Garousi J; Vorobyeva A; Altai M
Molecules; 2020 Jun; 25(11):. PubMed ID: 32526905
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of
Bragina O; von Witting E; Garousi J; Zelchan R; Sandström M; Orlova A; Medvedeva A; Doroshenko A; Vorobyeva A; Lindbo S; Borin J; Tarabanovskaya N; Sörensen J; Hober S; Chernov V; Tolmachev V
J Nucl Med; 2021 Apr; 62(4):493-499. PubMed ID: 32817142
[TBL] [Abstract][Full Text] [Related]
5. Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.
Lindbo S; Garousi J; Mitran B; Altai M; Buijs J; Orlova A; Hober S; Tolmachev V
J Nucl Med; 2018 Jan; 59(1):93-99. PubMed ID: 28864631
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Approaches for the Assessment of HER2 Expression in Breast Cancer by Radionuclide Imaging Using the Scaffold Protein [
Bragina O; Tashireva L; Loos D; Chernov V; Hober S; Tolmachev V
Pharmaceutics; 2024 Mar; 16(4):. PubMed ID: 38675107
[TBL] [Abstract][Full Text] [Related]
7. Direct In Vivo Comparison of
Tolmachev V; Bodenko V; Oroujeni M; Deyev S; Konovalova E; Schulga A; Lindbo S; Hober S; Bragina O; Orlova A; Vorobyeva A
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499504
[TBL] [Abstract][Full Text] [Related]
8. Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins.
Lindbo S; Garousi J; Åstrand M; Honarvar H; Orlova A; Hober S; Tolmachev V
Bioconjug Chem; 2016 Mar; 27(3):716-26. PubMed ID: 26781756
[TBL] [Abstract][Full Text] [Related]
9. Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [
Bragina O; Chernov V; Schulga A; Konovalova E; Hober S; Deyev S; Sörensen J; Tolmachev V
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370758
[TBL] [Abstract][Full Text] [Related]
10. Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart.
Garousi J; Xu T; Liu Y; Vorontsova O; Hober S; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015242
[TBL] [Abstract][Full Text] [Related]
11. Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle.
Garousi J; von Witting E; Borin J; Vorobyeva A; Altai M; Vorontsova O; Konijnenberg MW; Oroujeni M; Orlova A; Tolmachev V; Hober S
Biomaterials; 2021 Jan; 266():120381. PubMed ID: 33120197
[TBL] [Abstract][Full Text] [Related]
12. Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice.
Gainkam LO; Caveliers V; Devoogdt N; Vanhove C; Xavier C; Boerman O; Muyldermans S; Bossuyt A; Lahoutte T
Contrast Media Mol Imaging; 2011; 6(2):85-92. PubMed ID: 20936711
[TBL] [Abstract][Full Text] [Related]
13. Selection of the optimal macrocyclic chelators for labeling with
von Witting E; Garousi J; Lindbo S; Vorobyeva A; Altai M; Oroujeni M; Mitran B; Orlova A; Hober S; Tolmachev V
Eur J Pharm Biopharm; 2019 Jul; 140():109-120. PubMed ID: 31082509
[TBL] [Abstract][Full Text] [Related]
14. Reduction of renal activity retention of radiolabeled albumin binding domain‑derived affinity proteins using a non‑residualizing label strategy compared with a cleavable glycine‑leucine‑glycine‑lysine‑linker.
Lundmark F; Vorobyeva A; Liu Y; Lindbo S; Xu T; Oroujeni M; Rinne SS; Rosenström U; Garousi J
Mol Med Rep; 2024 Feb; 29(2):. PubMed ID: 38186305
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression.
Mitran B; Altai M; Hofström C; Honarvar H; Sandström M; Orlova A; Tolmachev V; Gräslund T
Amino Acids; 2015 Feb; 47(2):303-15. PubMed ID: 25425114
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m.
Garousi J; Lindbo S; Mitran B; Buijs J; Vorobyeva A; Orlova A; Tolmachev V; Hober S
Sci Rep; 2017 Nov; 7(1):14780. PubMed ID: 29116215
[TBL] [Abstract][Full Text] [Related]
17. Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein.
Garousi J; Ding H; von Witting E; Xu T; Vorobyeva A; Oroujeni M; Orlova A; Hober S; Gräslund T; Tolmachev V
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834262
[TBL] [Abstract][Full Text] [Related]
18. Dynamic and static small-animal SPECT in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy.
Melis M; de Swart J; de Visser M; Berndsen SC; Koelewijn S; Valkema R; Boerman OC; Krenning EP; de Jong M
J Nucl Med; 2010 Dec; 51(12):1962-8. PubMed ID: 21078795
[TBL] [Abstract][Full Text] [Related]
19. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
[TBL] [Abstract][Full Text] [Related]
20. Preparation and
Okarvi SM; Aljammaz I
Anticancer Res; 2018 May; 38(5):2823-2830. PubMed ID: 29715105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
